IL-21 Signaling in Immunity [version 1; referees: 3 approved]

F1000Research

Chi-Keung Wan¹  Warren J. Leonard¹ 

[1] Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethseda, Maryland, 20892, USA;

关键词: Antimicrobials & Drug Resistance;    Autoimmunity;    Cancer Therapeutics;    Cellular Microbiology & Pathogenesis;    HIV Infection & AIDS: Basic Science;    HIV Infection & AIDS: Clinical;    HIV Infection & AIDS: Vaccines;    Immune Response;    Immunity to Infections;    Immunomodulation;    Immunopharmacology & Hematologic Pharmacology;    Innate Immunity;    Leukemia & Proliferative Disorders of Hematic Cells;    Leukocyte Signaling & Gene Expression;    Virology;   

DOI  :  10.12688/f1000research.7634.1

来源: DOAJ

【 摘 要 】

IL-21 is a type I cytokine produced by T cells and natural killer T cells that has pleiotropic actions on a wide range of immune and non-immune cell types. Since its discovery in 2000, extensive studies on the biological actions of IL-21 have been performed in vitro and in vivo. Recent reports describing patients with primary immunodeficiency caused by mutations of IL21 or IL21R have further deepened our knowledge of the role of this cytokine in host defense. Elucidation of the molecular mechanisms that mediate IL-21’s actions has provided the rationale for targeting IL-21 and IL-21 downstream mediators for therapeutic purposes. The use of next-generation sequencing technology has provided further insights into the complexity of IL-21 signaling and has identified transcription factors and co-factors involved in mediating the actions of this cytokine. In this review, we discuss recent advances in the biology and signaling of IL-21 and how this knowledge can be potentially translated into clinical settings.

【 授权许可】

Unknown